BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that it has filed four new patent applications in the UK related to several novel cancer-specific antigen pairs or “fingerprints” across a range of oncology indications.

The new patent applications focus on three novel cancer-specific antigen fingerprints that have been identified by the Company and can be used to support the development of a pipeline of highly selective, cancer therapeutics utilising the Company’s proprietary Bi-Cygni® approach. This will further strengthen BiVictriX’s growing intellectual property portfolio and provide opportunities to widen the application of the Company’s Bi-Cygni® technology across several solid tumour and haematological cancers, demonstrating the broad utility of the approach. These filings are the next step in the Company’s strategy to broaden its patent portfolio both in the UK and internationally.

BiVictriX’s novel approach to cancer therapies relies on utilising its proprietary library of cancer-specific antigen co-expression fingerprints, or “twin antigens”, which are uniquely expressed on a cancer. The Company’s pipeline of Bi-Cygni® therapeutics are designed to selectively target these twin antigens which are present on tumour cells and largely absent from healthy cells, enabling the development of a novel class of next-generation anti-cancer therapies with potentially superior cancer selectivity and a significantly reduced side-effect profile. This approach has the potential to deliver better treatment outcomes for patients.

Tiffany Thorn, Chief Executive Officer of BiVictriX, commented: “We are excited to be expanding our existing patent portfolio across a wider range of cancer types that currently constitute areas of high unmet medical need, demonstrating the broad utility of our innovative Bi-Cygni® platform. The new patents, if approved, will provide broad protection for our pipeline assets, allowing the development of several generations of cancer-selective Bi-Cygni® therapeutics across a wide range of solid tumour and haematological cancers that constitute areas of urgent unmet need. I look forward to providing further updates regarding the application for these new patents as appropriate.”

The patent applications in BiVictriX’s growing portfolio are wholly owned by BiVictriX and, as such, are not subject to any licensing arrangements.